Stifel Starts Kalvista Pharmaceuticals Inc (KALV) at Buy

Stifel analyst Paul Matteis initiates coverage on Kalvista Pharmaceuticals Inc (NASDAQ: KALV) with a Buy rating and a price target of $33.00.

The analyst comments "Our optimism stems from a triangulation of pharmacokinetic data and various validated/predictive pre-clinical assays. Concurrently, we think clinical results from competitor BioCryst corroborate the viability of the oral kallikrein inhibitor approach but simultaneously leave room for improvement. As KALV plans to initiate a phase II trial by YE18, the company may also pursue HAE attack prevention with KVD900 or another molecule behind it. But acute HAE (even if the market shrinks some with the launch of Shire's Lanadelumab) is on its own a >$1Bn market. Kalvista also has a DME partnership with Merck for KVD001 which represents upside to our TP."

For an analyst ratings summary and ratings history on Kalvista Pharmaceuticals Inc click here. For more ratings news on Kalvista Pharmaceuticals Inc click here.

Shares of Kalvista Pharmaceuticals Inc closed at $18.76 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS